This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the …

Prostate CancerMetastatic Castration-resistant Prostate CancerCastration Resistant Prostatic Cancer

~Estimated

~$10 – $8,750

Janux TherapeuticsNCT05519449

Phase 1

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants wi…

Advanced Solid TumorAdvanced CancerMetastatic Cancer+19 more

~Estimated

~$10 – $7,500

MacroGenicsNCT06242470

Phase 2

A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer

The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and …

Prostate CancerRefractory CancerCastration Resistant Prostatic Cancer

~Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT04337580